1
|
Ciccone LP, Franzetti J, Bonora M, Ronchi S, Camarda AM, Charalampopoulou A, Facoetti A, Bazani A, Magro G, Vischioni B, Locati LD, Licitra L, Sauerwein WAG, Orlandi E. Charged particle radiotherapy for thyroid cancer. A systematic review. Crit Rev Oncol Hematol 2024; 202:104463. [PMID: 39098367 DOI: 10.1016/j.critrevonc.2024.104463] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2024] [Revised: 07/26/2024] [Accepted: 07/28/2024] [Indexed: 08/06/2024] Open
Abstract
The role of external beam radiotherapy (EBRT) in thyroid cancer (TC) remains contentious due to limited data. Retrospective studies suggest adjuvant EBRT benefits high-risk differentiated thyroid cancer (DTC) and limited-stage anaplastic thyroid carcinoma (ATC), enhancing locoregional control and progression-free survival when combined with surgery and chemotherapy. Intensity-modulated radiotherapy (IMRT) and particle therapy (PT), including protons, carbon ions, and Boron Neutron Capture Therapy (BNCT), represent advances in TC treatment. Following PRISMA guidelines, we reviewed 471 studies from January 2002 to January 2024, selecting 14 articles (10 preclinical, 4 clinical). Preclinical research focused on BNCT in ATC mouse models, showing promising local control rates. Clinical studies explored proton, neutron, or photon radiotherapy, reporting favorable outcomes and manageable toxicity. While PT shows promise supported by biological rationale, further research is necessary to clarify its role and potential combination with systemic treatments in TC management.
Collapse
Affiliation(s)
- Lucia Pia Ciccone
- Clinical Department, CNAO National Center for Oncological Hadrontherapy, Pavia 27100, Italy
| | - Jessica Franzetti
- Clinical Department, CNAO National Center for Oncological Hadrontherapy, Pavia 27100, Italy.
| | - Maria Bonora
- Clinical Department, CNAO National Center for Oncological Hadrontherapy, Pavia 27100, Italy
| | - Sara Ronchi
- Clinical Department, CNAO National Center for Oncological Hadrontherapy, Pavia 27100, Italy
| | - Anna Maria Camarda
- Clinical Department, CNAO National Center for Oncological Hadrontherapy, Pavia 27100, Italy
| | - Alexandra Charalampopoulou
- Radiobiology Unit, Research and Development Department, CNAO National Center for Oncological Hadrontherapy, Pavia 27100, Italy; Hadron Academy PhD Course, University School for Advanced Studies (IUSS), Pavia 27100, Italy
| | - Angelica Facoetti
- Radiobiology Unit, Research and Development Department, CNAO National Center for Oncological Hadrontherapy, Pavia 27100, Italy
| | - Alessia Bazani
- Medical Physics Unit, CNAO National Center for Oncological Hadrontherapy, Pavia 27100, Italy
| | - Giuseppe Magro
- Medical Physics Unit, CNAO National Center for Oncological Hadrontherapy, Pavia 27100, Italy
| | - Barbara Vischioni
- Clinical Department, CNAO National Center for Oncological Hadrontherapy, Pavia 27100, Italy
| | - Laura Deborah Locati
- Department of Internal Medicine and Therapeutics University of Pavia, Pavia 27100, Italy; Medical Oncology Unit, Istituti Clinici Scientifici Maugeri IRCCS, Pavia 27100, Italy
| | - Lisa Licitra
- Scientific Directorate, CNAO National Center for Oncological Hadrontherapy, Pavia 27100, Italy; Department of Head & Neck Medical Oncology 3, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan 20133, Italy; Department of Oncology & Haemato-Oncology, University of Milan, Milan 20122, Italy
| | - Wolfgang A G Sauerwein
- Deutsche Gesellschaft für Bor-Neutroneneinfangtherapie (DGBNCT), Essen, Germany; BNCT Global GmbH, Essen, Germany
| | - Ester Orlandi
- Clinical Department, CNAO National Center for Oncological Hadrontherapy, Pavia 27100, Italy; Department of Clinical, Surgical, Diagnostic, and Pediatric Sciences, University of Pavia, Pavia, Italy
| |
Collapse
|
2
|
Monti Hughes A, Schwint AE. Animal Tumor Models for Boron Neutron Capture Therapy Studies (Excluding Central Nervous System Solid Tumors). Cancer Biother Radiopharm 2022. [PMID: 36130136 DOI: 10.1089/cbr.2022.0054] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Translational research in adequate experimental models is necessary to optimize boron neutron capture therapy (BNCT) for different pathologies. Multiple radiobiological in vivo studies have been performed in a wide variety of animal models, studying multiple boron compounds, routes of compound administration, and a range of administration strategies. Animal models are useful for the study of the stability and potential toxicity of new boron compounds or delivery systems, BNCT theranostic strategies, the evaluation of biomarkers to monitor BNCT therapeutic and adverse effects, and to study the BNCT immune response by the host against tumor cells. This article will mention examples of these studies, highlighting the importance of experimental animal models for the advancement of BNCT. Animal models are essential to design novel, safe, and effective clinical BNCT protocols for existing or new targets for BNCT.
Collapse
Affiliation(s)
- Andrea Monti Hughes
- Departamento de Radiobiología, Centro Atómico Constituyentes, Comisión Nacional de Energía Atómica (CNEA), Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| | - Amanda E Schwint
- Departamento de Radiobiología, Centro Atómico Constituyentes, Comisión Nacional de Energía Atómica (CNEA), Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| |
Collapse
|
3
|
Importance of radiobiological studies for the advancement of boron neutron capture therapy (BNCT). Expert Rev Mol Med 2022; 24:e14. [PMID: 35357286 DOI: 10.1017/erm.2022.7] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Boron neutron capture therapy (BNCT) is a tumour selective particle radiotherapy, based on the administration of boron carriers incorporated preferentially by tumour cells, followed by irradiation with a thermal or epithermal neutron beam. BNCT clinical results to date show therapeutic efficacy, associated with an improvement in patient quality of life and prolonged survival. Translational research in adequate experimental models is necessary to optimise BNCT for different pathologies. This review recapitulates some examples of BNCT radiobiological studies for different pathologies and clinical scenarios, strategies to optimise boron targeting, enhance BNCT therapeutic effect and minimise radiotoxicity. It also describes the radiobiological mechanisms induced by BNCT, and the importance of the detection of biomarkers to monitor and predict the therapeutic efficacy and toxicity of BNCT alone or combined with other strategies. Besides, there is a brief comment on the introduction of accelerator-based neutron sources in BNCT. These sources would expand the clinical BNCT services to more patients, and would help to make BNCT a standard treatment modality for various types of cancer. Radiobiological BNCT studies have been of utmost importance to make progress in BNCT, being essential to design novel, safe and effective clinical BNCT protocols.
Collapse
|
4
|
Perona M, Majdalani ME, Rodríguez C, Nievas S, Carpano M, Rossini A, Longhino JM, Cabrini R, Pisarev MA, Juvenal GJ, Dagrosa MA. Experimental studies of boron neutron capture therapy (BNCT) using histone deacetylase inhibitor (HDACI) sodium butyrate, as a complementary drug for the treatment of poorly differentiated thyroid cancer (PDTC). Appl Radiat Isot 2020; 164:109297. [PMID: 32768887 DOI: 10.1016/j.apradiso.2020.109297] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2019] [Revised: 02/19/2020] [Accepted: 06/14/2020] [Indexed: 11/30/2022]
Abstract
PURPOSE The present study analyzed different protocols of administration of boronophenylalanine (BPA) and sodium butyrate (NaB) to increase the BNCT efficacy for poorly differentiated thyroid cancer (PDTC). MATERIALS AND METHODS Nude mice implanted with human PDTC cells (WRO) were distributed into four protocols: 1) BPA; 2) BPA + ip NaB; 3) BPA + oral NaB; 4) Control. Biodistribution and histologic studies were performed. LAT (BPA transporter) isoforms gene expression was assessed by RT-PCR. RESULTS Tumor growth delay was observed in animals of the Protocol #3 (p < 0.05). NaB (Protocol #2) increased tumor boron uptake 2-h post BPA injection (p < 0.05). On the other hand, NaB upregulated the expression of all the isoforms of the LAT transporter in vitro. Histologic studies showed a significant decrease of mitotic activity and an increase of vacuoles in tumors of Protocol #3. Neutrons alone or combined with NaB caused some tumor growth delay (p < 0.05), while in the BNCT and BNCT + NaB groups, there was a halt in tumor growth in 70 and 80% of the animals, respectively. CONCLUSIONS Intraperitoneally administration of NaB increased boron uptake while oral administration for a longer period of time induced tumor growth delay previous to BPA administration. The use of NaB via ip would optimize the irradiation results.
Collapse
Affiliation(s)
- M Perona
- Comisión Nacional de Energía Atómica (CNEA), Av. Gral Paz 1499 (1650), Buenos Aires, Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290 (1425) CABA, Argentina
| | - M E Majdalani
- Comisión Nacional de Energía Atómica (CNEA), Av. Gral Paz 1499 (1650), Buenos Aires, Argentina
| | - C Rodríguez
- Comisión Nacional de Energía Atómica (CNEA), Av. Gral Paz 1499 (1650), Buenos Aires, Argentina
| | - S Nievas
- Comisión Nacional de Energía Atómica (CNEA), Av. Gral Paz 1499 (1650), Buenos Aires, Argentina
| | - M Carpano
- Comisión Nacional de Energía Atómica (CNEA), Av. Gral Paz 1499 (1650), Buenos Aires, Argentina
| | - A Rossini
- Comisión Nacional de Energía Atómica (CNEA), Av. Gral Paz 1499 (1650), Buenos Aires, Argentina
| | - J M Longhino
- Comisión Nacional de Energía Atómica (CNEA), Av. Gral Paz 1499 (1650), Buenos Aires, Argentina
| | - R Cabrini
- Comisión Nacional de Energía Atómica (CNEA), Av. Gral Paz 1499 (1650), Buenos Aires, Argentina
| | - M A Pisarev
- Comisión Nacional de Energía Atómica (CNEA), Av. Gral Paz 1499 (1650), Buenos Aires, Argentina
| | - G J Juvenal
- Comisión Nacional de Energía Atómica (CNEA), Av. Gral Paz 1499 (1650), Buenos Aires, Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290 (1425) CABA, Argentina
| | - M A Dagrosa
- Comisión Nacional de Energía Atómica (CNEA), Av. Gral Paz 1499 (1650), Buenos Aires, Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290 (1425) CABA, Argentina. http://
| |
Collapse
|
5
|
Enomoto K, Hotomi M. Amino Acid Transporters as Potential Therapeutic Targets in Thyroid Cancer. Endocrinol Metab (Seoul) 2020; 35:227-236. [PMID: 32615707 PMCID: PMC7386108 DOI: 10.3803/enm.2020.35.2.227] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/08/2020] [Accepted: 06/09/2020] [Indexed: 12/31/2022] Open
Abstract
Thyroid cancer cells have a high amino acid demand for proliferation, invasion, and metastasis. Amino acids are taken up by thyroid cancer cells, both thyroid follicular cell and thyroid parafollicular cells (commonly called "C-cells"), via amino acid transporters. Amino acid transporters up-regulate in many cancers, and their expression level associate with clinical aggressiveness and prognosis. This is the review to discuss the therapeutic potential of amino acid transporters and as molecular targets in thyroid cancer.
Collapse
Affiliation(s)
- Keisuke Enomoto
- Department of Otolaryngology-Head and Neck Surgery, Wakayama Medical University, Wakayama, Japan
| | - Muneki Hotomi
- Department of Otolaryngology-Head and Neck Surgery, Wakayama Medical University, Wakayama, Japan
| |
Collapse
|
6
|
Rodriguez C, Carpano M, Curotto P, Thorp S, Casal M, Juvenal G, Pisarev M, Dagrosa MA. In vitro studies of DNA damage and repair mechanisms induced by BNCT in a poorly differentiated thyroid carcinoma cell line. RADIATION AND ENVIRONMENTAL BIOPHYSICS 2018; 57:143-152. [PMID: 29453554 DOI: 10.1007/s00411-017-0729-y] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/10/2017] [Accepted: 12/24/2017] [Indexed: 06/08/2023]
Abstract
Boron neutron capture therapy (BNCT) for aggressive tumors is based on nuclear reaction [10B (n, α) 7Li]. Previously, we demonstrated that BNCT could be applied for the treatment of undifferentiated thyroid carcinoma. The aim of the present study was to describe the DNA damage pattern and the repair pathways that are activated by BNCT in thyroid cells. We analyzed γH2AX foci and the expression of Ku70, Rad51 and Rad54, main effector enzymes of non-homologous end joining (NHEJ) and homologous recombination repair (HRR) pathways, respectively, in thyroid follicular carcinoma cells. The studied groups were: (1) C [no irradiation], (2) gamma [60Co source], (3) N [neutron beam alone], (4) BNCT [neutron beam plus 10 µg 10B/ml of boronphenylalanine (10BPA)]. The total absorbed dose was always 3 Gy. The results showed that the number of nuclear γH2AX foci was higher in the gamma group than in the N and BNCT groups (30 min-24 h) (p < 0.001). However, the focus size was significantly larger in BNCT compared to other groups (p < 0.01). The analysis of repair enzymes showed a significant increase in Rad51 and Rad54 mRNA at 4 and 6 h, respectively; in both N and BNCT groups and the expression of Ku70 did not show significant differences between groups. These findings are consistent with an activation of HRR mechanism in thyroid cells. A melanoma cell line showed different DNA damage pattern and activation of both repair pathways. These results will allow us to evaluate different blocking points, to potentiate the damage induced by BNCT.
Collapse
Affiliation(s)
- C Rodriguez
- Radiobiology Department (CAC, CNEA), 1499 Gral Paz Av, Buenos Aires, Argentina
| | - M Carpano
- Radiobiology Department (CAC, CNEA), 1499 Gral Paz Av, Buenos Aires, Argentina
| | - P Curotto
- RA-3-Investigation and Production Reactors (CAE, CNEA), 15 Presbítero González y Aragón Rd, Buenos Aires, Argentina
| | - S Thorp
- Instrumentation and Control Department (CAE, CNEA), 15 Presbítero González y Aragón Rd, Buenos Aires, Argentina
| | - M Casal
- Oncology Institute "Ángel H. Roffo"-University of Buenos Aires, 5481 San Martín Av, Ciudad Autónoma de Buenos Aires, Argentina
| | - G Juvenal
- Radiobiology Department (CAC, CNEA), 1499 Gral Paz Av, Buenos Aires, Argentina
- Scientific and Technical Research National Council (CONICET), 1917 Rivadavia St, Ciudad Autónoma de Buenos Aires, Argentina
| | - M Pisarev
- Radiobiology Department (CAC, CNEA), 1499 Gral Paz Av, Buenos Aires, Argentina
- Scientific and Technical Research National Council (CONICET), 1917 Rivadavia St, Ciudad Autónoma de Buenos Aires, Argentina
| | - M A Dagrosa
- Radiobiology Department (CAC, CNEA), 1499 Gral Paz Av, Buenos Aires, Argentina.
- Scientific and Technical Research National Council (CONICET), 1917 Rivadavia St, Ciudad Autónoma de Buenos Aires, Argentina.
| |
Collapse
|
7
|
González SJ, Pozzi ECC, Monti Hughes A, Provenzano L, Koivunoro H, Carando DG, Thorp SI, Casal MR, Bortolussi S, Trivillin VA, Garabalino MA, Curotto P, Heber EM, Santa Cruz GA, Kankaanranta L, Joensuu H, Schwint AE. Photon iso-effective dose for cancer treatment with mixed field radiation based on dose–response assessment from human and an animal model: clinical application to boron neutron capture therapy for head and neck cancer. ACTA ACUST UNITED AC 2017; 62:7938-7958. [DOI: 10.1088/1361-6560/aa8986] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
|
8
|
Sato A, Itoh T, Imamichi S, Kikuhara S, Fujimori H, Hirai T, Saito S, Sakurai Y, Tanaka H, Nakamura H, Suzuki M, Murakami Y, Baiseitov D, Berikkhanova K, Zhumadilov Z, Imahori Y, Itami J, Ono K, Masunaga S, Masutani M. Proteomic analysis of cellular response induced by boron neutron capture reaction in human squamous cell carcinoma SAS cells. Appl Radiat Isot 2015; 106:213-9. [DOI: 10.1016/j.apradiso.2015.08.001] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2015] [Revised: 08/03/2015] [Accepted: 08/04/2015] [Indexed: 10/23/2022]
|
9
|
Perona M, Rodríguez C, Carpano M, Thomasz L, Nievas S, Olivera M, Thorp S, Curotto P, Pozzi E, Kahl S, Pisarev M, Juvenal G, Dagrosa A. Improvement of the boron neutron capture therapy (BNCT) by the previous administration of the histone deacetylase inhibitor sodium butyrate for the treatment of thyroid carcinoma. RADIATION AND ENVIRONMENTAL BIOPHYSICS 2013; 52:363-373. [PMID: 23636505 DOI: 10.1007/s00411-013-0470-0] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/29/2012] [Accepted: 04/10/2013] [Indexed: 06/02/2023]
Abstract
We have shown that boron neutron capture therapy (BNCT) could be an alternative for the treatment of poorly differentiated thyroid carcinoma (PDTC). Histone deacetylase inhibitors (HDACI) like sodium butyrate (NaB) cause hyperacetylation of histone proteins and show capacity to increase the gamma irradiation effect. The purpose of these studies was to investigate the use of the NaB as a radiosensitizer of the BNCT for PDTC. Follicular thyroid carcinoma cells (WRO) and rat thyroid epithelial cells (FRTL-5) were incubated with 1 mM NaB and then treated with boronophenylalanine ¹⁰BPA (10 μg ¹⁰B ml⁻¹) + neutrons, or with 2, 4-bis (α,β-dihydroxyethyl)-deutero-porphyrin IX ¹⁰BOPP (10 μg ¹⁰B ml⁻¹) + neutrons, or with a neutron beam alone. The cells were irradiated in the thermal column facility of the RA-3 reactor (flux = (1.0 ± 0.1) × 10¹⁰ n cm⁻² s⁻¹). Cell survival decreased as a function of the physical absorbed dose in both cell lines. Moreover, the addition of NaB decreased cell survival (p < 0.05) in WRO cells incubated with both boron compounds. NaB increased the percentage of necrotic and apoptotic cells in both BNCT groups (p < 0.05). An accumulation of cells in G2/M phase at 24 h was observed for all the irradiated groups and the addition of NaB increased this percentage. Biodistribution studies of BPA (350 mg kg⁻¹ body weight) 24 h after NaB injection were performed. The in vivo studies showed that NaB treatment increases the amount of boron in the tumor at 2-h post-BPA injection (p < 0.01). We conclude that NaB could be used as a radiosensitizer for the treatment of thyroid carcinoma by BNCT.
Collapse
Affiliation(s)
- M Perona
- Department of Radiobiology, National Atomic Energy Commission-CNEA, Avenida General Paz 1499, San Martín 1650, Buenos Aires, Argentina
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Faião-Flores F, Coelho PRP, Toledo Arruda-Neto JD, Maria-Engler SS, Tiago M, Capelozzi VL, Giorgi RR, Maria DA. Apoptosis through Bcl-2/Bax and cleaved caspase up-regulation in melanoma treated by boron neutron capture therapy. PLoS One 2013; 8:e59639. [PMID: 23527236 PMCID: PMC3603877 DOI: 10.1371/journal.pone.0059639] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2012] [Accepted: 02/16/2013] [Indexed: 11/18/2022] Open
Abstract
Boron neutron capture therapy (BNCT) is a binary treatment involving selective accumulation of boron carriers in a tumor followed by irradiation with a thermal or epithermal neutron beam. The neutron capture reaction with a boron-10 nucleus yields high linear energy transfer (LET) particles, alpha and (7)Li, with a range of 5 to 9 µm. These particles can only travel very short distances and release their damaging energy directly into the cells containing the boron compound. We aimed to evaluate proliferation, apoptosis and extracellular matrix (ECM) modifications of B16F10 melanoma and normal human melanocytes after BNCT. The amounts of soluble collagen and Hsp47, indicating collagen synthesis in the ECM, as well as the cellular markers of apoptosis, were investigated. BNCT decreased proliferation, altered the ECM by decreasing collagen synthesis and induced apoptosis by regulating Bcl-2/Bax in melanoma. Additionally, BNCT also increased the levels of TNF receptor and the cleaved caspases 3, 7, 8 and 9 in melanoma. These results suggest that multiple pathways related to cell death and cell cycle arrest are involved in the treatment of melanoma by BNCT.
Collapse
Affiliation(s)
- Fernanda Faião-Flores
- Laboratory of Biochemistry and Biophysics, Butantan Institute, São Paulo, Brazil
- Faculty of Medicine, University of São Paulo, São Paulo, Brazil
| | | | - João Dias Toledo Arruda-Neto
- Physics Institute, University of São Paulo, São Paulo, Brazil
- CEPESq/UniÍtalo – Italy-Brazilian University Center, São Paulo, Brazil
| | - Silvya Stuchi Maria-Engler
- Department of Clinical Chemistry & Toxicology, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil
| | - Manoela Tiago
- Department of Clinical Chemistry & Toxicology, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil
| | | | - Ricardo Rodrigues Giorgi
- Laboratory for Cellular and Molecular Endocrinology (LIM-25) School of Medicine, University of São Paulo, São Paulo, Brazil
- Santo Amaro University UNISA, São Paulo, Brazil
| | - Durvanei Augusto Maria
- Laboratory of Biochemistry and Biophysics, Butantan Institute, São Paulo, Brazil
- * E-mail:
| |
Collapse
|
11
|
Perona M, Pontiggia O, Carpano M, Thomasz L, Thorp S, Pozzi E, Simian M, Kahl S, Juvenal G, Pisarev M, Dagrosa A. In vitro studies of cellular response to DNA damage induced by boron neutron capture therapy. Appl Radiat Isot 2011; 69:1732-6. [DOI: 10.1016/j.apradiso.2011.03.044] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2010] [Revised: 03/21/2011] [Accepted: 03/31/2011] [Indexed: 11/26/2022]
|
12
|
Dagrosa A, Carpano M, Perona M, Thomasz L, Nievas S, Cabrini R, Juvenal G, Pisarev M. Studies for the application of boron neutron capture therapy to the treatment of differentiated thyroid cancer. Appl Radiat Isot 2011; 69:1752-5. [PMID: 21570311 DOI: 10.1016/j.apradiso.2011.02.030] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2010] [Revised: 02/15/2011] [Accepted: 02/17/2011] [Indexed: 10/18/2022]
Abstract
The aim of these studies was to evaluate the possibility of treating differentiated thyroid cancer by BNCT. These carcinomas are well controlled with surgery followed by therapy with (131)I; however, some patients do not respond to this treatment. BPA uptake was analyzed both in vitro and in nude mice implanted with cell lines of differentiated thyroid carcinoma. The boron intracellular concentration in the different cell lines and the biodistribution studies showed the selectivity of the BPA uptake by this kind of tumor.
Collapse
Affiliation(s)
- A Dagrosa
- Department of Radiobiology, National Atomic Energy Commission (CNEA), San Martin, Argentina.
| | | | | | | | | | | | | | | |
Collapse
|
13
|
Wittig A, Huiskamp R, Moss RL, Bet P, Kriegeskotte C, Scherag A, Hilken G, Sauerwein WAG. Biodistribution of (10)B for Boron Neutron Capture Therapy (BNCT) in a mouse model after injection of sodium mercaptoundecahydro-closo-dodecaborate and l-para-boronophenylalanine. Radiat Res 2009; 172:493-9. [PMID: 19772470 DOI: 10.1667/rr1700.1] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
In boron neutron capture therapy, the absorbed dose from the (10)B(n,alpha)(7)Li reaction depends on the (10)B concentration and (10)B distribution in the irradiated volume. Thus compounds used in BNCT should have tumor-specific uptake and low accumulation in normal tissues. This study compares in a mouse model the (10)B uptake in different organs as delivered by l-para-boronophenylalanine (BPA, 700 mg/kg body weight, i.p.) and/or sodium mercaptoundecahydro-closo-dodecaborate (BSH, 200 mg/kg body weight, i.p). After BSH injection, the (10)B concentration was high in kidneys (20 +/- 12 microg/g) and liver (20 +/- 12 microg/g) but was low in brain (1.0 +/- 0.8 microg/g) and muscle (1.9 +/- 1.2 microg/g). After BPA injection, the (10)B concentration was high in kidneys (38 +/- 25 microg/g) and spleen (17 +/- 8 microg/g) but low in brain (5 +/- 3 microg/g). After combined BPA and BSH injection, the effect on the absolute (10)B concentration was additive in all organs. The ratio of the (10)B concentrations in tissues and blood differed significantly for the two compounds depending on the compound combination, which implies a different uptake profile for normal organs.
Collapse
Affiliation(s)
- Andrea Wittig
- Department of Radiation Oncology, University Hospital Essen, University Duisburg-Essen, University Hospital Essen, Essen, Germany.
| | | | | | | | | | | | | | | |
Collapse
|
14
|
Wittig A, Collette L, Moss R, Sauerwein W. Early clinical trial concept for boron neutron capture therapy: A critical assessment of the EORTC trial 11001. Appl Radiat Isot 2009; 67:S59-62. [DOI: 10.1016/j.apradiso.2009.03.012] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
15
|
Kabalka GW, Yao ML, Marepally SR, Chandra S. Biological evaluation of boronated unnatural amino acids as new boron carriers. Appl Radiat Isot 2009; 67:S374-9. [PMID: 19398346 DOI: 10.1016/j.apradiso.2009.03.104] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
There is a pressing need for new and more efficient boron delivery agents to tumor cells for use in boron neutron capture therapy (BNCT). A class of boronated unnatural cyclic amino acids has demonstrated a remarkable selectivity toward tumors in animal and cell culture models, far superior to currently used agents in clinical BNCT. One of these amino acids, 1-amino-3-boronocyclopentanecarboxylic acid (ABCPC), has shown a tumor to blood ratio of 8 and a tumor to normal brain ratio of nearly 21 in a melanoma bearing mouse model. This work represents further biological characterization of this compound for tumor targeting in an EMT6 murine mammary carcinoma mouse model and a T98G human glioblastoma cell line. Female BALB/c mice bearing EMT6 tumors were injected with the fructose complex form of racemic mixtures of cis and trans isomers of ABCPC in identical concentrations. Boron concentrations were measured in the tumor, blood, brain, skin, and liver tissues at 1, 3, and 5 h post-injection. These observations revealed a remarkable difference in racemic mixtures of cis and trans isomers in tumor targeting by boron. This implies that further separation of the L and D forms of this compound may enhance tumor targeting to an even higher degree than that provided by the racemic mixtures. Since the uptake measurements were made in homogenized tumor and normal tissues, little is known about the subcellular location of the boron arising from the various isomeric forms of the amino acid. To study subcellular delivery of boron from ABCPC in T98G human glioblastoma cells, we employed secondary ion mass spectrometry (SIMS) based technique of ion microscopy, which is capable of quantitatively imaging isotopic (elemental) gradients in cells and tissues at 500 nm spatial resolution. The T98G cells were exposed to the nutrient medium containing 100 ppm boron equivalent of a mixture of both L and D isomers of ABCPC in the form of a fructose complex for 1 h. Following this treatment, the cells were fast frozen, freeze-fractured, and freeze-dried for SIMS analysis. Within an hour of exposure, ABCPC provided partitioning of intracellular to extracellular boron of 3/1. SIMS imaging revealed that boron from ABCPC was distributed throughout the cell, including the nucleus. This level of boron delivery within an hour of exposure is superior to p-boronophenylalanine (BPA) and sodium borocaptate (BSH), which have been previously studied by SIMS in the same cell line. These encouraging observations provide compelling support for further isomeric separations of ABCPC into the D and L forms for enhanced tumor targeting and continued testing of these compounds as new boron carriers in BNCT.
Collapse
Affiliation(s)
- G W Kabalka
- Departments of Radiology and Chemistry, The University of Tennessee, Knoxville, TN, USA.
| | | | | | | |
Collapse
|
16
|
|